Stocks Comparison
Cellyan Biotechnology vs NU Skin Enterprises: revenue, profit, margins and growth compared
Cellyan Biotechnology brought in $20.3M of revenue in fiscal 2025, NU Skin Enterprises $1.5B in fiscal 2025. Revenue changed by +21.7% at Cellyan Biotechnology and -14.3% at NU Skin Enterprises on the year before, so Cellyan Biotechnology grew faster. Cellyan Biotechnology kept -0.1% of its revenue as net profit, NU Skin Enterprises 10.8%. Free cash flow was $499.3K at Cellyan Biotechnology and $46M at NU Skin Enterprises.
Side by side, latest fiscal year
| HKPD | NUS | |
|---|---|---|
| Fiscal year ended | FY2025 (March 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $20.3M | $1.5B |
| Revenue growth | +21.7% | -14.3% |
| Net income | -$27.1K | $160.2M |
| Net margin | -0.1% | 10.8% |
| Free cash flow | $499.3K | $46M |
| Free cash flow margin | 2.5% | 3.1% |
| Earnings per share (diluted) | -$0.00 | $3.18 |
| Cash | $748.7K | $238.6M |
| Debt | $1.9M | $224.2M |
| Price to earnings | n/a | 1.5 |
| Market value | $5.4M | $225.4M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #434 of 646 · Health care | #123 of 646 · Health care |
Over the years
Questions about Cellyan Biotechnology and NU Skin Enterprises
Which is bigger by revenue, Cellyan Biotechnology or NU Skin Enterprises?
NU Skin Enterprises is bigger by revenue: $1.5B in fiscal 2025, against $20.3M for Cellyan Biotechnology in fiscal 2025.
Which keeps more of its revenue as profit, Cellyan Biotechnology or NU Skin Enterprises?
Cellyan Biotechnology had a net margin of -0.1% in fiscal 2025; NU Skin Enterprises had 10.8% in fiscal 2025.
Which grew revenue faster, Cellyan Biotechnology or NU Skin Enterprises?
In their latest fiscal years revenue changed by +21.7% at Cellyan Biotechnology and -14.3% at NU Skin Enterprises.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.